Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Inteliquet Announces Presbyterian Healthcare Services to Join Consortium to Drive Better Patient Matching in Clinical Trials

  • Presbyterian Supporting National Prioritization of Clinical Effectiveness Through Understanding Patients as Individuals

Inteliquet announced Presbyterian Healthcare Services of Albuquerque, New Mexico will join Inteliquet’s Cancer Center Research Consortium as a leader in personalized, comprehensive oncological care in New Mexico and champion of leading-edge clinical research.

“We select members of the Cancer Center Research Consortium based on their ability to deliver personalized care, and their ability to transfer that approach to more effective research,” said Dr. Tandy Tipps, Senior Vice President, Healthcare Organizations at Inteliquet. “Presbyterian has earned a reputation for investing in teams and a process that in turn take the time to understand and serve patients as individuals. Our experience has been that leads to better research, and that access to clinical trials can be provided to patients on the most appropriate basis.”

Recommended AI News: Litmus Expands Partnership With Google Cloud to Power Edge-to-Cloud Smart Factory Solutions

All consortium members are able to leverage the integration technology in OncWeb™ at their centers. The AI technology provided securely and quickly identifies eligible patients for the right trials. It more accurately recognizes what is important about individuals within patient populations, and better informs care decisions for specific patients, as well as determine the suitability of different trials.

Related Posts
1 of 21,718

“The experts at Presbyterian Cancer Care are dedicated to delivering compassionate, individualized care for our patients,” said Norbert Topf M.D., chief quality/medical officer, Presbyterian Healthcare Services. “Joining the Consortium allows our team of oncology and research nurses and technologists, surgical oncologists, and radiation oncologists to work together with a larger community of centers and scale our personalized approach to incorporating the latest research, treatment and clinical trial options to create the best treatment plan for each patient.”

OncWeb™ provides cancer centers the ability to scale and enhance their existing patient-first focus, regardless of size, type and therapeutic focus, while improving clinical trial enrollment and reducing recruitment frustrations and administrative burden. It provides physicians the tools to more accurately understands patient populations, promote well-informed patient care decisions, as well as determining a site’s suitability when considering a specific trial.

Recommended AI News: SlashNext Enhances Listing On Palo Alto Networks Cortex XSOAR Marketplace

Deidentified Consortium data allows physicians at each center to conduct patient treatment comparisons with hundreds of their peers. Centers are able to deploy digitally transcribed protocol criteria, up-to-date clinical trial patient matching and querying, cohort identification and analysis, optimized clinical trial feasibility, and truth in treatment analytics.

A user-curated Watch List ensures awareness of patients who may soon become eligible for a clinical trial. Personalized care is further augmented by Real-world Evidence, nightly data refreshers, patient comparison, and a longitudinal view of a patient’s journey via de-identified protected health information.

Recommended AI News: AI Robotics Startup Mech-Mind Completes Series C Funding Led by Tech Giant Meituan

Comments are closed.